UCDAVIS HEALTH | SCHOOL OF MEDICINE

Medical Microbiology & Immunology
MMI 291 Seminar Series
Emerging Challenges in Microbiology and Immunology

MMI 291 Seminar Series

Current Theme: Interdisciplinary Research
Fall Quarter 2019 – CRN 51546
Friday Seminar – 12:10-1 p.m.

"Immunopathogenesis of Arbovirus: Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)"

Bio

A native of Seoul, Jung earned his bachelor's and master's degrees from Seoul National University. He moved to the United States in 1985 and earned his Ph.D. in microbiology at the University of California, Davis four years later. He completed post-doctoral training at Harvard Medical School and was later appointed as a faculty at Harvard Medical School Microbiology and Molecular Genetic Department, and eventually served as chair of the Tumor Virology Division. He became the first Korean-born faculty to be promoted to a tenured professorship at Harvard University. Jung has been awarded South Korea's 2012 Ho-Am Prize in Medicine, an honor that is often referred to as the Korean equivalent of the Nobel Prize. Dr. Jung is regarded as a preeminent expert in the field of virus-induced cancer, emerging virus and programmed cell death. Virus-induced cancer includes Kaposi's sarcoma and lymphoma; emerging virus includes misquote-borne virus (Dengue virus and Zika virus), and tick-borne virus (Severe Fever with Thrombocytopenia virus); and programmed cell death includes apoptosis, autophagy, pyroptosis and necroptosis. In addition, Dr. Jung's research is highly translational to the field of cancers, autoimmune diseases and emerging viral diseases.

Publications

Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets.Kwak JE[1], Kim YI[2], Park SJ[2], Yu MA[2], Kwon HI[2], Eo S[1], Kim TS[3], Seok J[3], Choi WS[2], Jeong JH[2], Lee H[4], Cho Y[4], Kwon JA[4], Jeong M[4], Maslow JN[4], Kim YE[5], Jeon H[5], Kim KK[5], Shin EC[1,3], Song MS[2], Jung JU[6], Choi YK[7], Park SH[8,9].

Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis. Younho Choi,[1] Su-Jin Park,[2] Yinyan Sun,[3] Ji-Seung Yoo,[1] Raghavendra Sumanth Pudupakam,[1] Suan-Sin Foo,[1] Woo-Jin Shin,[1] Sally B. Chen,[1] Philip N. Tsichlis,[4] Won-Ja Lee,[5] Jong-Soo Lee,[6] Wenhui Li,[3] Benjamin Brennan,[7] Young-Ki Choi,[2] and Jae U. Jung[1,*]

Ferret animal model of severe fever with thrombocytopenia syndrome phlebovirus for human lethal infection and pathogenesis. Park SJ[1,2], Kim YI[1,2], Park A[3], Kwon HI[1,2], Kim EH[1,2], Si YJ[1,2], Song MS[1,2], Lee CH[4], Jung K[3], Shin WJ[3], Zeng J[3], Choi Y[3], Jung JU[5], Choi YK[6,7].

December 6

Jae U. Jung, Ph.D.
Chair and Distinguished Professor of the Molecular Microbiology & Immunology Department, Keck School of Medicine of University of Southern Ca., Director, UCS Institute of Emerging Pathogens & Immune Diseases

December 6, 2019
12:10 – 1 p.m.
GBSF 1005

Medical Microbiology & Immunology
School of Medicine

Seminar Contact:
Veronica Keys
530-752-9401
vlkeys@ucdavis.edu

We hope to see you there!